Hisco announced that the subsidiary Sichuan Hisco Pharmaceutical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration on January 6, 2026. HSK39297 tablets are suitable for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors. According to China's new chemical drug registration classification regulations, their drug registration classification is chemical class 1. HSK39297 is an efficient selective complement factor B small molecule inhibitor independently developed by the company. By inhibiting FB activity, it blocks the activation of the bypass pathway and the complement amplification cycle, thereby inhibiting the activity of the entire complement pathway. It aims to treat various diseases mediated by abnormal complement activation.

Hisco announced that the subsidiary Sichuan Hisco Pharmaceutical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration on January 6, 2026. HSK39297 tablets are suitable for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors. According to China's new chemical drug registration classification regulations, their drug registration classification is chemical class 1. HSK39297 is an efficient selective complement factor B small molecule inhibitor independently developed by the company. By inhibiting FB activity, it blocks the activation of the bypass pathway and the complement amplification cycle, thereby inhibiting the activity of the entire complement pathway. It aims to treat various diseases mediated by abnormal complement activation.